Beta-Blocker Use and Lung Cancer Mortality in a Nationwide Cohort Study of Patients with Primary Non–Small Cell Lung Cancer

Abstract

Background: b-Adrenergic receptor blockers have been associated with improved survival among patients with different types of malignancies, but available data for patients with nonsmall cell lung cancer (NSCLC) are contradictory and limited to small hospital-based studies. We therefore aimed to investigate whether b-blocker use at the time of cancer diagnosis is associated with lung cancer mortality in the largest general population-based cohort of patients with NSCLC to date.Methods: For this retrospectively defined nationwide cohort study, we used prospectively collected data from Swedish population and health registers. Through the Swedish Cancer Register, we identified 18,429 patients diagnosed with a primary NSCLC between 2006 and 2014 with follow-up to 2015. Cox regression was used to estimate the association between b-blocker use at time of cancer diagnosis ascertained from the Prescribed Drug Register and cancer-specific mortality identified from the Cause of Death Register.Results: Over a median follow-up of 10.2 months, 14,994 patients died (including 13,398 from lung cancer). Compared with nonuse, b-blocker use (predominantly prevalent use, 93%) was not associated with lung cancer mortality [HR (95% confidence interval): 1.01 (0.97-1.06)]. However, the possibility that diverging associations for specific b-blockers and some histopathologic subtypes exist cannot be excluded.Conclusions: In this nationwide cohort of patients with NSCLC, b-blocker use was not associated with lung cancer mortality when assessed in aggregate in the total cohort, but evidence for some b-blockers is less conclusive.Impact: Our results do not indicate that b-blocker use at lung cancer diagnosis reduces the cancer-specific mortality rate in patients with NSCLC.

Increased Sympathetic Nervous System Impairs Prognosis in Lung Cancer Patients: A Scoping Review of Clinical Studies

“…This tool evaluated four methodological components: reporting, external validity, internal validity (bias and confounding), and power. Only two studies, in the reporting [ 35 , 49 ] and external validity [ 36 , 41 ], achieved the maximum score (11 and 3, respectively). No study reached the maximum score in internal validity (bias and selection bias) and power items.…”

ß-Adrenoreceptors in Human Cancers

“…There have been numerous retrospective studies that evaluated the impact of BB use on clinical outcome in patients with NSCLC. Some of these population-based cohort studies showed no association between BB use and reduced mortality among lung cancer patients [ 98 , 99 , 100 ]. However, others indicated that BB use was indeed associated with an improved outcome because BB use during chemotherapy treatment improved OS in patients with metastatic NSCLC [ 101 ].…”

Anti-proliferative effects of beta-blocker propranolol on human lung cancer and noncancer cells

“…Lung cancer is one of the most prevalent cancer type worldwide along with more than 1.7 million of deaths annually among cancer-related mortalities (1)(2)(3). The prognosis of lung cancer is still not at the desired point despite the advanced therapeutic strategies such as tumorectomy, chemo-/radio-therapy, immune therapy, etc.…”